Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
PARIS and NEW YORK, Sept. 12, 2016 -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it will release the results of the Phase IIa clinical trial for high blood pressure (QGC001 program) on September 29, 2016, after the close of Euronext Paris.
As a reminder, this clinical trial evaluated around 30 patients with high blood pressure at four clinical investigation centres in France, under the supervision of Prof. Michel Azizi, Clinical Investigation Centre at Georges Pompidou European Hospital, Paris. It was a randomised, double-blinded study, with cross-over, to compare the effects of the product QGC001 (500 mg morning and night) with those of a placebo. It also aimed to analyse the pharmacodynamic effects of QGC001 on several hormonal biomarkers.
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
Twitter: @ALQGC_EN
LinkedIn: Quantum Genomics
Quantum Genomics Lionel Ségard Chairman & Chief Executive Officer +33 1 85 34 77 77 Quantum Genomics Marc Karako CFO – Investor Relations +33 1 85 34 77 75 [email protected] ACTUS finance et communication (Europe) Jean-Michel Marmillon Press Relations +33 1 53 67 36 73 [email protected] The Ruth Group (U.S.) Lee Roth / Kirsten Thomas Investor / Public Relations +1 646-536-7012 / +1 508-280-6592
